Manifold Bio Demonstrates Million-Scale Experimental Validation of AI-Driven Protein Binder Design with NVIDIA
Manifold Bio, a platform therapeutics company pioneering direct-to-vivo drug discovery, today announced a joint study with NVIDIA to validate Proteina-Complexa, NVIDIA's generative model for protein binder design. Manifold used its proprietary platform to test 1 million binder designs against 127 targets in a single multiplexed experiment, measuring over 100 million protein-protein interactions. The study identified specific binders to 68% of targets tested, establishing Proteina-Complexa as a competitive generative model for protein binder design.
Manifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics Platform
Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with massively multiplexed in vivo measurement, today announced the expansion of its executive leadership team with the appointment of Paula Cobb as Chief Operating Officer.
Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases
Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The partnership will apply Manifold's proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to create multiple next-generation BBB shuttles for the treatment of neurological and neurodegenerative diseases.
Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform
Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and Tencent. Existing investors Playground Global, Fifty Years, and FAST by GETTYLAB also participated. The investment will enable Manifold Bio to advance its internal drug programs and expand its next-generation protein engineering platform to support additional programs and partnerships.
